CDD-2101：a botanical drug for the treatment of constipation-related indications.

CDD
Overview

CDD-2101 is a botanical drug candidate for the treatment of constipation-related indications in the form of granules for oral use. By identifying and standardizing the active ingredients of the traditional Chinese medicine formula "MaZiRenWan," it has become the first botanical drug developed in Hong Kong to be approved by the U.S. Food and Drug Administration for clinical research.

  • CDD-2101：a botanical drug for the treatment of constipation-related indications. 0
Commercialisation opportunities
Licensing agreement
Problem addressed

Patients with constipation typically undergo lifestyle modifications together with pharmacological therapeutics but are often not completely satisfied with their treatments due to efficacy and safety concerns. Most of these therapeutics are for symptom relief only which leave patients with a long-term disease burden. Novel treatments are needed to target the specific underlying cause(s) of constipation.

Innovation
  • CDD-2101 is a granular form of the classic Chinese herbal formulation MaZiRenWan with high quality control measures that ensure the safety and therapeutic consistency of the drug.
Key impact
  • CDD-2101 restores gut dysbiosis by modulating the gut microbiota-derived short chain fatty acids, biogenic amines, fatty acid amides, and bile acids in patients with chronic constipation.
  • CDD-2101 has well-documented clinical efficacy and minimal safety concerns.
  • High quality control measures of CDD-2101 pioneers the modernization of Chinese herbal formulation to meet international standards for drug development.
Award
  • Silver Award, the 50th International Exhibition of Inventions Geneva
Application
  • An anti-constipation agent for oral use
  • US FDA botanical drug

Patent

  • China patent: CN117137927A
  • China patent: CN118518660A
  • China patent: CN118518807A
  • US patent: US2025082660A1

Funded by Innovation and Technology Commission (ITC) of the Hong Kong Government, Centre for Chinese Herbal Medicine Drug Development Limited (the Centre) was established in September 2020, to accelerate the development of Chinese Herbal Medicine (CHM)-based drugs, and serve as a strategic platform to promote collaborations among local and international researchers, institutions and industry. The Centre aims to achieve the goal by enhancing the quality of pre-clinical and clinical CHM research and transforming the results into pharmaceutical products for international markets. In particular, the Centre develops treatments and cures for diseases such as ulcerative colitis and chronic constipation. It also supports the incubation of new CHM-based pharmaceutical start-ups that will target the global market, and nurtures talent for CHM research in Hong Kong.

Enquiry
Related Innovations